Hardman & Co: Q&A on Fidelity European Trust (FEV)
Hardman & Co Video | Analyst interview
Q&A on Fidelity European Trust (FEV) | Key strengths to weather headwinds
Fidelity European Trust is the topic of conversation when Hardman & Co Investment Companies Analyst Riccardo Bindi joins DirectorsTalk Interviews.
Riccardo talks us through his note that was released prior to the AGM, concerns over Ukraine, rise in inflation and sharp style sector rotation, confidence from Fidelity European Trusts long-term philosophy and process, and just how important the Fidelity analysts are.
Listen to the interview here :
If you are interested in meeting the company, you can register your interest here
|
To contact us:
Hardman & Co London EC2R 8AE www.hardmanandco.com Follow us on Twitter @HardmanandCo |
Contact: Riccardo Bindi
|
|
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 hours ago Cambridge Cognition Holdings
- 6 hours ago Shell
- 6 hours ago Centrica
- 7 hours ago Optima Health
- 7 hours ago Centrica